| | 1999 | | 2004 | | 2008 | | Unique total§ | | | N | % | N | % | N | % | N | % | Had GT in this yr → | 118 | | 164 | | 63 | | 906 | |
| Age, years*† | | | | | | | | | Median (IQR) | 40 | (36, 47) | 43 | (39, 48) | 41 | (38, 51) | 43 | (38, 49) | <35 | 18 | 15.2 | 17 | 10.4 | 9 | 14.3 | 110 | 12.1 | 35–49 | 78 | 66.1 | 110 | 67.1 | 36 | 57.1 | 583 | 64.4 | 50+ | 22 | 18.6 | 37 | 22.6 | 18 | 28.6 | 213 | 23.5 |
| Gender† | | | | | | | | | Female | 25 | 21.2 | 36 | 22.0 | 24 | 38.1 | 208 | 23.0 | Male | 93 | 78.8 | 128 | 78.0 | 39 | 61.9 | 698 | 77.0 |
| Race† | | | | | | | | | White | 73 | 61.9 | 75 | 45.7 | 22 | 34.9 | 448 | 49.4 | Black | 30 | 25.4 | 65 | 39.6 | 30 | 47.6 | 334 | 36.9 | Other/unknown | 15 | 12.7 | 24 | 14.6 | 11 | 17.5 | 124 | 13.7 |
| HIV Risk† | | | | | | | | | Heterosexual | 31 | 26.3 | 53 | 32.3 | 27 | 42.9 | 266 | 29.4 | IDU | 12 | 10.2 | 15 | 9.1 | 9 | 14.3 | 102 | 11.3 | MSM | 70 | 59.3 | 85 | 51.8 | 23 | 36.5 | 487 | 53.8 | Other/unknown | 5 | 4.2 | 11 | 6.7 | 4 | 6.4 | 51 | 5.6 |
| Insurance*† | | | | | | | | | Private | 54 | 45.8 | 58 | 35.4 | 21 | 33.3 | 381 | 42.0 | Public | 49 | 41.5 | 93 | 56.7 | 37 | 58.7 | 444 | 49.0 | Other/unknown | 15 | 12.7 | 13 | 7.9 | 5 | 7.9 | 81 | 8.9 |
| CD4+ count, cells/mm3* | | | | | | | | | Median (IQR) | 225.5 | (105, 360) | 272 | (163, 432) | 170 | (64, 325) | 267.5 | (124, 433) | <200 | 54 | 45.8 | 56 | 34.2 | 36 | 57.1 | 347 | 38.3 | 200–349 | 32 | 27.1 | 46 | 28.0 | 11 | 17.5 | 229 | 25.3 | 350–499 | 16 | 13.6 | 34 | 20.7 | 7 | 11.1 | 162 | 17.9 | 500+ | 15 | 12.7 | 26 | 15.8 | 8 | 12.7 | 150 | 16.6 | Missing | 1 | 0.8 | 2 | 1.2 | 1 | 1.6 | 18 | 2.0 |
| Nadir CD4+ count, cells/mm3*† | | | | | | | | | Median (IQR) | 99 | (34, 213) | 126 | (40, 247) | 55 | (20, 206) | 105 | (32, 247) | <50 | 38 | 32.2 | 52 | 31.1 | 29 | 46.0 | 278 | 30.7 | 50–199 | 44 | 37.3 | 52 | 31.7 | 18 | 28.6 | 306 | 33.8 | 200–349 | 24 | 20.3 | 38 | 23.2 | 12 | 19.0 | 184 | 20.3 | 350+ | 9 | 7.6 | 20 | 12.3 | 4 | 6.4 | 101 | 11.2 | Missing | 3 | 2.5 | 3 | 1.8 | 0 | 0.0 | 37 | 4.1 |
| HIV RNA viral load, copies/mL* | | | | | | | | | Median log (IQR) | 4.6 | (3.9, 5.0) | 4.2 | (3.6, 4.8) | 4.5 | (3.7, 5.0) | 4.3 | (3.6, 4.9) | 1,000–9,999 | 35 | 29.7 | 65 | 39.6 | 23 | 36.5 | 368 | 40.6 | 10,000–99,999 | 54 | 45.8 | 69 | 42.1 | 23 | 36.5 | 363 | 40.1 | ≥100,000 | 29 | 24.6 | 30 | 18.3 | 17 | 27.0 | 175 | 19.3 |
| AIDS* | 99 | 83.9 | 133 | 81.1 | 52 | 82.5 | 728 | 80.4 |
| Antiretroviral exposure* | | | | | | | | | 3TC/FTC exposed | 110 | 93.2 | 158 | 96.3 | 62 | 98.4 | 856 | 94.5 | NRTI exposed | 118 | 100.0 | 164 | 100.0 | 63 | 100.0 | 905 | 99.9 | NNRTI exposed | 78 | 66.1 | 128 | 78.1 | 47 | 74.6 | 656 | 72.4 | PI exposed (any) | 105 | 89.0 | 144 | 87.8 | 55 | 87.3 | 799 | 88.2 | Ritonavir-boosted PI exposed | 7 | 5.9 | 109 | 66.5 | 51 | 81.0 | 478 | 52.8 | Mono-dual NRTI exposed | 88 | 74.6 | 99 | 60.4 | 33 | 52.4 | 515 | 56.8 | Triple-class exposed (TCE) | 55 | 46.6 | 94 | 57.3 | 32 | 50.8 | 496 | 54.8 | Only cART exposed | 22 | 18.6 | 54 | 32.9 | 24 | 38.1 | 299 | 33.0 | Any exposure to all 3 classes of agents (NRTI, NNRTI, and PI) | 71 | 60.2 | 109 | 66.5 | 39 | 61.9 | 566 | 62.5 |
| ARV exposure duration among those exposed with complete and evaluable ARV history, median months* | n | Median | n | Median | n | Median | n | Median | 3TC/FTC exposed | 110 | 22 | 158 | 43 | 62 | 58 | 856 | 37 | NRTI exposed | 118 | 44 | 164 | 71 | 63 | 73 | 905 | 62 | NNRTI exposed | 78 | 12 | 128 | 19 | 47 | 23 | 656 | 20 | PI exposed (any) | 105 | 28 | 144 | 51 | 55 | 56 | 799 | 43 | Ritonoavir-boosted PI exposed | 7 | 5 | 108 | 23 | 51 | 36 | 477 | 21 | Mono-dual NRTI exposed | 88 | 19 | 98 | 12 | 31 | 7 | 503 | 13 | Triple-class exposed (TCE) | 38 | 11 | 75 | 46 | 29 | 57 | 394 | 38 | Only cART exposed | 11 | 15 | 54 | 36 | 24 | 39 | 299 | 34 |
| Number of ARVs exposed to date, median | 118 | 6 | 164 | 8 | 63 | 7 | 906 | 7 |
| Duration of ARV exposure, years, median | 118 | 4.0 | 164 | 6.2 | 63 | 6.2 | 906 | 5.3 |
|
|